| Product Name | Abiraterone-d4 |
| Product Code | DA-A007-23 |
| Chemical name | Abiraterone-d4 |
| Synonyms | (3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol-d4; (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl-d4)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Androsta-5,16-dien-3-ol, 17-(3-pyridinyl-2,4,5,6-d4)-, (3β); |
| Impurity | NA |
| CAS Number | 2122245-62-7 |
| Alternate CAS # | NA |
| Molecular form | C24H27D4NO |
| Appearance | White to Off-White Solid |
| Melting Point | NA |
| Mol. Weight | 353.53 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | stable isotopes,impurities,metabolites,pharmaceutical standards,intermediates,Fine Chemicals |
| Boiling Point | NA |
| Applications | Labelled Abiraterone. A steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
| NA |
